Abstract
Infliximab has demonstrated remarkable effects on controlling uveitis in patients with Behçet’s disease (BD). However, there is no way except for discontinuation of infliximab treatment in patients who are intolerant to the agent due to hypersensitivity reactions. We here report successful switching from infliximab to adalimumab in a BD patient. Treatment with infliximab had maintained clinical remission in the patient having refractory ocular lesions to cyclosporine until the patient had experienced repeated infliximab-related infusion reactions. Discontinuation of the therapy led to another ocular attacks immediately. Switching to adalimumab induced clinical remission again. Our experience suggest adalimumab is a safe and effective option for patients having hypersensitivity to infliximab.
This is a preview of subscription content, log in via an institution to check access.
References
Sfikakis PP, Theodossiadis PG, Katsiari CG et al (2001) Effect of infliximab on sight-threatening panuveitis in Behçet’s disease. Lancet 358:295–296
Tugal-Tutkun I, Mudun A, Urgancioglu M et al (2005) Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet’s disease: an open-label trial. Arthritis Rheum 52:2478–2484
Ohno S, Nakamura S, Hori S et al (2004) Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet’s disease with refractory uveoretinitis. J Rheumatol 31:1362–1368
Sfikakis PP (2002) Behçet’s disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 61(Suppl 2):ii51–ii53
Sfikakis PP, Markomichelakis N, Alpsoy E et al (2007) Anti-TNF therapy in the management of Behcet’s disease–review and basis for recommendations. Rheumatology (Oxford) 46:736–741
Hanauer SB, Feagan BG, Lichtenstein GR et al (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial [comment]. Lancet 359:1541–1549
Sands BE, Blank MA, Patel K et al (2004) Long-term treatment of rectovaginal fistulas in Crohn’s disease: response to infliximab in the ACCENT II study. Clin Gastroenterol Hepatol 2:912–920
Papadakis KA, Shaye OA, Vasiliauskas EA et al (2005) Safety and efficacy of adalimumab (D2E7) in Crohn’s disease patients with an attenuated response to infliximab. Am J Gastroenterol 100:75–79
Oussalah A, Babouri A, Chevaux JB et al (2009) Adalimumab for Crohn’s disease with intolerance or lost response to infliximab: a 3-year single-centre experience. Aliment Pharmacol Ther 29:416–423
Mushtaq B, Saeed T, Situnayake RD et al (2007) Adalimumab for sight-threatening uveitis in Behçet’s disease. Eye 21:824–825
van Laar JA, Missotten T, van Daele PL et al (2007) Adalimumab: a new modality for Behçet’s disease? Ann Rheum Dis 66:565–566
Hale S, Lightman S (2006) Anti-TNF therapies in the management of acute and chronic uveitis. Cytokine 33:231–237
Imrie FR, Dick AD (2007) Biologics in the treatment of uveitis. Curr Opin Ophthalmol 18:481–486
Theodossiadis PG, Markomichelakis NN, Sfikakis PP (2007) Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina 27:399–413
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Takase, K., Ohno, S., Ideguchi, H. et al. Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis. Rheumatol Int 31, 243–245 (2011). https://doi.org/10.1007/s00296-009-1178-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-009-1178-y